7YQ9

Crystal structure of BRD4 bromodomain 1 (BD1) in complex with N-[2-(1H-indol-3-yl)ethyl]-3-(trifluoromethyl)[1,2,4]triazolo[4,3-b]pyridazin-6-amine

7YQ9 の概要

• エントリーDOI: 10.2210/pdb7yq9/pdb
• 分子名称: Bromodomain-containing protein 4, CHLORIDE ION, N-[2-(1H-indol-3-yl)ethyl]-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-b]pyridazin-6-amine, ... (5 entities in total)
• 機能のキーワード: brd4, bet inhibitor, complex, transcription
• 由来する生物種: Homo sapiens (human)
• タンパク質・核酸の鎖数: 2
• 化学式量合計: 30906.05

構造登録者

Kim, J.H.,Lee, B.I. (登録日: 2022-08-05, 公開日: 2023-01-18, 最終更新日: 2023-11-29)

主引用文献

Kim, J.H.,Pandit, N.,Yoo, M.,Park, T.H.,Choi, J.U.,Park, C.H.,Jung, K.Y.,Lee, B.I.
Crystal structure of [1,2,4]triazolo[4,3-b]pyridazine derivatives as BRD4 bromodomain inhibitors and structure-activity relationship study.
Sci Rep, 13:10805-10805, 2023

PubMed Abstract: BRD4 contains two tandem bromodomains (BD1 and BD2) that recognize acetylated lysine for epigenetic reading, and these bromodomains are promising therapeutic targets for treating various diseases, including cancers. BRD4 is a well-studied target, and many chemical scaffolds for inhibitors have been developed. Research on the development of BRD4 inhibitors against various diseases is actively being conducted. Herein, we propose a series of [1,2,4]triazolo[4,3-b]pyridazine derivatives as bromodomain inhibitors with micromolar IC values. We characterized the binding modes by determining the crystal structures of BD1 in complex with four selected inhibitors. Compounds containing [1,2,4] triazolo[4,3-b]pyridazine derivatives offer promising starting molecules for designing potent BRD4 BD inhibitors.

PubMed: 37402749
DOI: 10.1038/s41598-023-37527-w

実験手法

X-RAY DIFFRACTION (1.5 Å)